RT Journal Article
T1 Influence of IL28B polymorphisms on response to a lower-than-standard dose peg-IFN-α 2a for genotype 3 chronic hepatitis C in HIV-coinfected patients.
A1 López-Cortés, Luis F
A1 Ruiz-Valderas, Rosa
A1 Jimenez-Jimenez, Luis
A1 González-Escribano, María F
A1 Torres-Cornejo, Almudena
A1 Mata, Rosario
A1 Rivero, Antonio
A1 Pineda, Juan A
A1 Marquez-Solero, Manuel
A1 Viciana, Pompeyo
K1 Infecciones por VIH
K1 Hepatitis C Crónica
K1 Interferón alfa
K1 Glicoles de Polietileno
K1 Ribavirina
AB BACKGROUNDData on which to base definitive recommendations on the doses and duration of therapy for genotype 3 HCV/HIV-coinfected patients are scarce. We evaluated the efficacy of a lower peginterferon-α 2a dose and a shorter duration of therapy than the current standard of care in genotype 3 HCV/HIV-coinfected patients.METHODS AND FINDINGSPilot, open-label, single arm clinical trial which involved 58 Caucasian HCV/HIV-coinfected patients who received weekly 135 µg peginterferon-α 2a plus ribavirin 400 mg twice daily during 20 weeks after attaining undetectable viremia. The relationships between baseline patient-related variables, including IL28B genotype, plasma HCV-RNA, ribavirin dose/kg, peginterferon-α 2a and ribavirin levels with virological responses were analyzed. Only 4 patients showed lack of response and 5 patients dropped out due to adverse events related to the study medication. Overall, sustained virologic response (SVR) rates were 58.3% by intention-to-treat and 71.4% by per protocol analysis, respectively. Among patients with rapid virologic response (RVR), SVR and relapses rates were 92.6% and 7.4%, respectively. No relationships were observed between viral responses and ribavirin dose/kg, peginterferon-α 2a concentrations, ribavirin levels or rs129679860 genotype.CONCLUSIONSWeekly 135 µg pegIFN-α 2a could be as effective as the standard 180 µg dose, with a very low incidence of severe adverse events. A 24-week treatment duration appears to be appropriate in patients achieving RVR, but extending treatment up to just 20 weeks beyond negativization of viremia is associated with a high relapse rate in those patients not achieving RVR. There was no influence of IL28B genotype on the virological responses.
PB Public Library of Science
YR 2012
FD 2012-01-03
LK http://hdl.handle.net/10668/844
UL http://hdl.handle.net/10668/844
LA en
NO López-Cortés LF, Ruiz-Valderas R, Jimenez-Jimenez L, González-Escribano MF, Torres-Cornejo A, Mata R, et al. Influence of IL28B polymorphisms on response to a lower-than-standard dose peg-IFN-α 2a for genotype 3 chronic hepatitis C in HIV-coinfected patients. PLoS ONE; 7(1):e28115
NO TRIAL REGISTRATION ClinicalTrials.gov NCT00553930. Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't;
DS RISalud
RD Apr 5, 2025